Published in Br J Clin Pharmacol on October 01, 2011
Targeting integrin and integrin signaling in treating thrombosis. Arterioscler Thromb Vasc Biol (2014) 0.93
Talin Modulation by a Synthetic N-Acylurea Derivative Reduces Angiogenesis in Human Endothelial Cells. Int J Mol Sci (2017) 0.75
Antiplatelet and anti-proliferative action of disintegrin from Echis multisquamatis snake venom. Croat Med J (2017) 0.75
Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes? Cardiol Res (2013) 0.75
Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies. Thromb J (2016) 0.75
Radiolabeled tirofiban - a potential radiopharmaceutical for detection of deep venous thrombosis. Drug Des Devel Ther (2016) 0.75
Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature (1984) 14.25
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31
Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med (1997) 4.36
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med (2002) 4.25
Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest (1979) 4.12
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet (1998) 4.03
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med (1994) 3.96
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med (2001) 3.85
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med (2004) 3.07
A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest (1983) 3.05
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med (2001) 2.83
Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med (2009) 2.49
GPIIb-IIIa: the responsive integrin. Cell (1991) 2.32
Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet (2000) 2.27
Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem (1992) 2.18
Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. Proc Natl Acad Sci U S A (1983) 2.09
An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br J Haematol (1974) 2.01
The formation of Ca++-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis. Blood (1981) 1.86
Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia. Blood (1980) 1.80
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol (2000) 1.45
Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest (1989) 1.33
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation (2001) 1.32
7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol (1997) 1.24
Reconstitution of the purified platelet fibrinogen receptor. Fibrinogen binding properties of the glycoprotein IIb-IIIa complex. J Biol Chem (1985) 1.22
Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin. Blood (1984) 1.21
The platelet fibrinogen receptor. Semin Hematol (1985) 1.20
Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation (1999) 1.19
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation (1994) 1.15
Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature (1975) 1.13
Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood (1985) 1.13
Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation (1998) 1.12
Clinical pharmacology of eptifibatide. Am J Cardiol (1997) 1.10
Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation (1998) 1.08
Fibrinogen-binding properties of the human platelet glycoprotein IIb-=IIIa complex: a study using crossed-radioimmunoelectrophoresis. Blood (1982) 1.07
A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. Arterioscler Thromb Vasc Biol (2006) 1.04
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation (1995) 1.03
PLATELETS IN THROMBOGENESIS: MECHANISM AND INHIBITION OF PLATELET AGGREGATION. Ann R Coll Surg Engl (1965) 1.02
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J (2009) 1.02
Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation (2001) 0.98
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation (2000) 0.97
Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation (1998) 0.96
Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res (1983) 0.95
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation (2000) 0.94
Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation (2001) 0.94
Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition. Biochemistry (2009) 0.93
AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists. J Thromb Haemost (2006) 0.91
Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol (2002) 0.91
Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol (2000) 0.90
Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med (2000) 0.89
RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation. J Thromb Haemost (2009) 0.87
Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol (2002) 0.85
Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol (1995) 0.85
Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists. Platelets (2007) 0.85
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. J Thromb Haemost (2009) 0.85
Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation (1998) 0.84
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol (1996) 0.81
Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation (1997) 0.81
Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem Pharmacol (1987) 0.79
Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thromb Thrombolysis (2001) 0.79
The incidence and clinical predictors of early stent thrombosis in patients with acute coronary syndrome. Am Heart J (2010) 0.79
The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. Pharmacogenomics J (2002) 0.79
Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. Am Heart J (2000) 0.79
Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited. Catheter Cardiovasc Interv (2002) 0.79
Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol (2003) 0.78
Polymorphisms in platelet glycoproteins Ia and IIIa are associated with arterial thrombosis and carotid atherosclerosis in type 2 diabetes. Thromb Haemost (2010) 0.78
Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists. J Thromb Thrombolysis (2000) 0.78
Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol (2002) 0.77
Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. Cardiovasc Drugs Ther (2003) 0.76
Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys. Eur J Pharmacol (1997) 0.76
Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. Am J Cardiol (2000) 0.76
Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators. Am J Cardiol (2001) 0.76
Current issues with glycoprotein IIb-IIIa antagonists. Curr Drug Targets (2011) 0.75